NEW YORK, Jan. 25, 2011 /PRNewswire-Asia-FirstCall/ --
American Oriental Bioengineering, Inc. (NYSE: AOB), ("the Company"
or "AOBO"), a pharmaceutical company dedicated to improving
healthcare through the development, manufacture and
commercialization of a broad range of prescription and
over-the-counter ("OTC") products, today announced that its
Chairman and Chief Executive Officer, Mr. Tony Liu and Chief Financial Officer, Ms.
Lily Li were Chinese entrepreneur
representatives on China's
President Hu Jintao's delegation
during the official state visit to the
United States in January 2011.
During the state visit, the management attended various forums and
symposiums held by both the U.S. and Chinese government officials.
Additionally, the company has signed a US contract research
organization (CRO) for its ongoing FDA program.
Mr. Tony Liu, Chairman and CEO of
AOBO, commented, "We are greatly honored to have been selected as
Chinese entrepreneur representatives on President Hu's delegation.
This invitation affirms AOBO's position as a leading pharmaceutical
company in China."
About American Oriental Bioengineering, Inc.
American Oriental Bioengineering, Inc. is a pharmaceutical
company dedicated to improving health through the development,
manufacture and commercialization of a broad range of prescription
and over-the-counter products.
Forward-Looking Statements
Statements made in this press release are forward-looking and
are made pursuant to the safe harbor provisions of the Securities
Litigation Reform Act of 1995. Such statements involve risks
and uncertainties that may cause actual results to differ
materially from those set forth in these statements. The
economic, competitive, governmental, technological and other
factors identified in the Company's filings with the Securities and
Exchange Commission, including the Form 10-K for the year ended
December 31, 2009, may cause actual
results or events to differ materially from those described in the
forward looking statements in this press release. The Company
undertakes no obligation to publicly update or revise any
forward-looking statements, whether because of new information,
future events, or otherwise.
Contact:
|
|
ICR, LLC
|
|
Christine Duan or Ashley
Ammon
|
|
203-682-8200
|
|
|
SOURCE American Oriental Bioengineering, Inc.